常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.45/0.06
|
|
企業價值
112.95M
|
| 資產負債 |
|
每股賬面淨值
0.97
|
| 現金流量 |
|
現金流量率
0.25
|
| 損益表 |
|
收益
124.96M
|
|
每股收益
1.75
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/07 20:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild tomoderate pain. |

0.7605 
